Biota signs new flu diagnostic agreement
Wednesday, 24 March, 2004
Biota (ASX:BTA) has signed a new agreement with its US-based flu diagnostics partner Thermo Electron giving it a profit share in a second influenza diagnostic kit, FLU OIA A/B.
The new agreement is similar to a previous profit share arrangement with Thermo for the FLU OIA test, which brought AUD$2.3 million of revenues into the company in the first half of this financial year.
CEO Peter Molloy said a US$750,000 payment to Thermo to contribute towards product development costs would be fully offset by expected revenues from the new product during the second half of the current financial year, and the company expects to see significant revenues from the two tests over the next few years.
The two companies hope to expand the market for flu diagnostics. Outside the US, Thermo has exclusive marketing rights for both products in Europe, Japan and Australia/New Zealand, while Biota's territory includes Asia and the rest of the world.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
